Blood, stool and tissue tests to find returning cancer early after treatment
Checks samples for returning breast cancer, melanoma or gut neuroendocrine tumors.
Plain-language title generated from the registry record
Registry title: Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed solid tumor at an early or locally advanced stage who are planned for, or have had, treatment meant to remove all of the disease.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Early stage or locally advanced solid tumor, with treatment meant to remove all of the disease planned or already done
- Earlier treatment
- Treatment meant to remove all of the disease is planned or has already been given
Read by machine on 9 November 2026.
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT05196087
- Record updated
- 28 September 2026
- Original description
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.Read full original descriptionShow less
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Inclusion: Patients with histological confirmation of a solid tumor; Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment; Patient must be ≥ 18 years old; All patients must have signed and dated an informed consent form.
Exclusion: None.